[HTML] nih.gov

[HTML][HTML] Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts

CA Thompson, T Stürmer - Diabetes Care, 2023 - ncbi.nlm.nih.gov
In this issue of Diabetes Care, Bezin et al.(1) report the findings of a populationbased case-
control study from France on the potential effects of glucagon-like peptide 1 receptor …
被引用次数：27 相关文章 所有 6 个版本
[HTML] diabetesjournals.org

[引用][C] Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023; 46: 384–390

J Bezin, C Mathieu, JL Faillie, A Pariente - Diabetes Care, 2023 - Am Diabetes Assoc
We read with great interest the comments by Endo et al.(1), Manas-Martinez and Gimeno-
Orna (2), and Smits and van Raalte (3) on our article (4). They underline several limitations …
被引用次数：2 相关文章 所有 4 个版本
[HTML] diabetesjournals.org

[引用][C] Comment on Bezin et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384–390

M Endo, MY Roth, TS Tylee, A DeSantis… - Diabetes …, 2023 - Am Diabetes Assoc
We read with great interest the article by Bezin et al.(1). Glucagon-like peptide 1 receptor
agonist (GLP-1 RA) exposure in rodents is associated with thyroid C-cell hyperplasia, tumor …
被引用次数：3 相关文章 所有 3 个版本

GLP-1 receptor agonists and the risk of thyroid cancer

J Bezin, A Gouverneur, M Pénichon, C Mathieu… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists
(RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND …
被引用次数：96 相关文章 所有 5 个版本

No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial

L Hegedüs, SI Sherman, RM Tuttle… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE To describe the changes in serum levels of calcitonin in liraglutide-and placebo-
treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular …
被引用次数：42 相关文章 所有 6 个版本
[HTML] nih.gov

Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial

MA Nauck, TJ Jensen, C Rosenkilde, S Calanna… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE This study explored neoplasm risk with liraglutide versus placebo in the
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome …
被引用次数：55 相关文章 所有 8 个版本
[HTML] nih.gov

[HTML][HTML] Do GLP-1–based therapies increase cancer risk?

MA Nauck, N Friedrich - Diabetes care, 2013 - ncbi.nlm.nih.gov
Cases of pancreatitis have been described in connection with the use of exenatide (1),
liraglutide (2) and other glucagon-like peptide (GLP)-1 receptor agonists. From these …
被引用次数：140 相关文章 所有 10 个版本
[PDF] academia.edu

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of …

T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup… - Diabetes …, 2007 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—Main inclusion criteria were patients aged≥ 18
years with type 2 diabetes and A1C≥ 7.5 and≤ 10.0%(diet) or≥ 7.0 and≤ 9.5%(mono …
被引用次数：573 相关文章 所有 13 个版本
[HTML] diabetesjournals.org

Differences between randomized clinical trial patients and real-world initiators of the glucagon-like peptide 1 receptor agonist liraglutide

JS Knudsen, RW Thomsen, A Pottegård… - Diabetes …, 2018 - Am Diabetes Assoc
Randomized controlled trials (RCTs) are considered the gold standard for determining
efficacy and safety of new drugs. Successful randomization addresses known and unknown …
被引用次数：21 相关文章 所有 7 个版本

Thyroid safety in patients treated with liraglutide

M Gallo - Journal of Endocrinological Investigation, 2013 - Springer
During the last years, various novel anti-diabetic drugs have considerably enriched the
therapeutic armamentarium for subjects with Type 2 diabetes. In the meantime, much …
被引用次数：45 相关文章 所有 5 个版本